GF-CART01 / GenomeFrontier Therap - LARVOL DELTA

Cellares and GenomeFrontier Therapeutics Partner to Evaluate Automated Manufacturing for GF-CART01 on the Cell Shuttle Platform (Businesswire) - "The collaboration will evaluate the translation of GenomeFrontier’s virus-free manufacturing process to the Cell Shuttle, with a focus on supporting transfection unit operation using Cellares’ proprietary integrated electroporator. The partnership marks Cellares’ first development collaboration in Asia and is intended to support GenomeFrontier’s U.S. clinical initiative as it advances GF-CART01."

Licensing / partnership • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

Long-term Study to Evaluate Safety and Persistence of GF-CART01 (clinicaltrials.gov) - P=N/A | N=18 | Enrolling by invitation | Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Long-term Study to Evaluate Safety and Persistence of GF-CART01 (clinicaltrials.gov) - P=N/A | N=18 | Not yet recruiting | Sponsor: GenomeFrontier Therapeutics TW Co., Ltd.

New trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Waldenstrom Macroglobulinemia

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects with Relapsed or Refractory B-Cell Hematological Malignancies (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: GenomeFrontier Therapeutics TW Co., Ltd.

CAR T-Cell Therapy • New P1 trial • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Waldenstrom Macroglobulinemia